Andere talen Biocon Limited

Aandelen

BIOCON

INE376G01013

Beurs gesloten - NSE India S.E. Andere beurzen 13:42:29 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
298,6 ^INR	-2,48%		+6,57%	+19,59%

20/04	Biocon Limited krijgt goedkeuring van de Zuid-Afrikaanse regelgevende instantie voor gezondheidsproducten voor zijn verticaal geïntegreerde, complexe geneesmiddel Tacrolimus-capsule met de sterkten 0,5 mg, 1 mg en 5 mg in Zuid-Afrika	CI
18/04	Biocon uit India ontwikkelt zijn eigen versie van Wegovy, klinische test waarschijnlijk volgend jaar	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Natural Biocon (India) CFO Passes Away	11:48
Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	20/04
India's Biocon developing its own version of Wegovy, clinical trial likely next year	18/04
Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18/04
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17/04
Biocon Board to Consider Dividend for Fiscal 2024	11/04
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03/04
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	01/04
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	28/03
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	27/03
Updates On Aflibercept BPCIA Litigation	26/03
Biocon Limited Receives an Order from the Reserve Bank of India	22/03
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15/03
Biocon's CFO Resigns	15/03
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer	14/03
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14/03
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14/03
Biocon Limited Announces Executive Appointments	04/03
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada	04/03
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara	01/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Biocon Limited

Aandelen

BIOCON

INE376G01013

Andere talen

Filters